$CYNO (Cynosure, Inc.)

$CYNO {{ '2016-07-26T17:07:03+0000' | timeago}} • Announcement

$CYNO said it got approval from Korean Ministry of Food and Drug Safety (MFDS) to market SculpSure for non-invasive lipolysis of abdomen and flanks. The product will be marketed through its direct sales force in Korea beginning in 3Q16. SculpSure is effective non-invasive treatment that eliminates up to 24% of treated fat in 25-minute procedure.

$GILD {{ '2017-07-27T19:17:21+0000' | timeago}} • Webcast

$GILD stated that for Genvoya, it is starting to see performance trends similar to that of the US in other countries like Germany. The company is seeing good uptake in Spain and Italy. France has also done extraordinarily well in just four months to become the leading naïve and switch product.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$GILD {{ '2017-07-27T19:04:57+0000' | timeago}} • Webcast

For HCV, $GILD’s total revenues in the US were $1.9Bil in 2Q17, down 17% YoY and up 13% sequentially. The QoQ increase was primarily due to a change in inventory and the timing of patient starts. In Europe, total HCV revenue was $591MM, down 24% YoY and up 21% from 1Q17.

$GILD {{ '2017-07-27T19:00:11+0000' | timeago}} • Webcast

$GILD is seeing strong uptake of its TAF-based regimens in the US and Europe. In the US, total HIV and HBV revenues were $2.6Bil for 2Q17, up 19% YoY and up 10% sequentially. In Europe, total HIV and HBV revenues were $732MM, down 3% YoY and up 5% sequentially. The YoY decrease was driven by negative foreign exchange.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$VAR {{ '2017-07-27T13:52:33+0000' | timeago}} • Announcement

Medical devices company $VAR has entered into a strategic collaboration with PetCure Oncology for the treatment of pets suffering from cancer. Under the partnership, Varian's software suite will be deployed across PetCure's veterinary cancer care centers. PetCure will acquire six Varian Halcyon treatment systems for use in select sites in the US.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

$GILD {{ '2017-07-24T13:41:56+0000' | timeago}} • Announcement

$GILD announced results from two Phase 3 studies evaluating the efficacy and safety of a fixed-dose combination of bictegravir (BIC) and emtricitabine/tenofovir alafenamide (FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. This regimen has been well tolerated with low rates of discontinuations due to adverse events.

$GILD {{ '2017-07-18T20:14:00+0000' | timeago}} • Announcement

$GILD said the US FDA has approved Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults previously treated with or without an NS5A inhibitor-containing regimen. The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$GILD {{ '2017-07-13T13:10:29+0000' | timeago}} • Announcement

$GILD said its Marketing Authorization Application for an investigational, once-daily single tablet regimen containing bictegravir and emtricitabine/tenofovir alafenamide, formulations for treatment of HIV-1 infection in adults, has been fully validated. Currently, they are under evaluation by the European Medicines Agency.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$VAR {{ '2017-07-11T12:14:17+0000' | timeago}} • Announcement

$VAR begins advanced breast cancer treatments using Edge radiosurgery system in combination with respiratory gating. The Edge radiosurgery system enables clinicians to attack tumors from outside the body using carefully shaped high-energy X-rays.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

Recent Transcripts

VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, July 26 2017 - 3:00pm
PHG (Koninklijke Philips N.V)
Monday, July 24 2017 - 8:00am
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ELMD (Electromed, Inc.)
Tuesday, May 16 2017 - 1:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
RMTI (Rockwell Medical, Inc.)
Tuesday, May 9 2017 - 8:30pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
NVDQ (Novadaq Technologies Inc.)
Wednesday, May 3 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm

AlphaGraphics you may like